BioSpace News Archive

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), an oncology company, is presenting new preclinical data for CRB-601 today in a poster presentation at the Society for Immunotherapy of Cancer (SITC) Annual Meeting in Boston.

Seagen Inc. (Nasdaq: SGEN) today announced that data from the company’s diverse pipeline of targeted cancer therapy candidates will be presented at the Society for Immunotherapy of Cancer’s (SITC) Annual Meeting being held November 8-12 in Boston.

Celularity Inc. today announced that it will present preclinical data on the development of its novel placental-derived allogeneic genetically modified natural killer (NK) cell therapy program CYNK-101 in combination with avelumab.

Triumvira Immunologics today announced preclinical data for its investigational TAC-T cell therapies CLDN18.2-TAC T and GUCY2C-TAC T, and data on HER2-specific TAC-T products.

Ankyra Therapeutics today announced that new, preclinical data highlighting the potential of the company’s lead program, ANK-101, an IL-12-based treatment, to deliver potent anti-tumor responses following intratumoral administration will be presented during a poster presentation at the Society for Immunotherapy of Cancer (SITC) 37th Annual Meeting.

Repertoire® Immune Medicines presented research today conducted with the company’s proprietary DECODE™ platform, which characterizes the cellular response to disease, identifying novel therapeutic targets in human papillomavirus (HPV) 16 and HPV 33-positive tumors.

Venture Exchange (“TSXV”) has approved the Company’s application to list its common shares (the “Shares”) on the TSXV. The Shares will commence trading on the TSXV under the ticker symbol “MGRO” at the opening of the Market on November 11, 2022.

Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”) today reported financial results and business updates for the third quarter of 2022.

Anebulo Pharmaceuticals, Inc. today announced financial results for the three months ended September 30, 2022 and recent updates.

OncoNano Medicine, Inc. today announced the presentation of data on its pre-clinical candidate ONM-501 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer (SITC) in Boston, Massachusetts.